Here are the 10-Q quarterly reports from Sangamo Therapeutics Inc (SGMO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SGMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMO filings page.
Sangamo Therapeutics reports a first‑quarter 2026 net loss of $30,995 thousand on revenues of $1,442 thousand, down from $6,437 thousand a year earlier, as operating expenses remained high at $33,388 thousand.
Cash and cash equivalents were $27,586 thousand as of March 31, 2026, against total liabilities of $78,920 thousand and a stockholders’ deficit of $18,955 thousand.
The company raised $23,346 thousand through an underwritten equity and warrant offering and $3,732 thousand via its at‑the‑market program but still discloses substantial doubt about its ability to continue as a going concern without significant near‑term financing or partnering transactions.
Sangamo also received a Nasdaq delisting determination due to minimum bid price noncompliance; its common stock was suspended from Nasdaq trading on May 5, 2026 and began trading on the OTCQB Venture Market, while the company appeals the delisting.
Sangamo Therapeutics (SGMO) reported a sharp step-down in revenue and a wider loss for Q3 2025. Revenue was $581 thousand, down from $49.4 million a year ago, reflecting lower collaboration activity. The quarter’s net loss was $34.9 million (basic and diluted EPS of $(0.11)), versus net income of $10.7 million in Q3 2024. Operating expenses were $36.1 million, with R&D at $28.1 million and G&A at $8.0 million.
Liquidity remains tight with a going concern warning. Cash and cash equivalents were $29.6 million as of September 30, 2025. Net cash used in operating activities was $72.8 million for the nine months. Stockholders’ equity fell to $6.2 million from $22.8 million at year-end 2024. To fund operations, the company raised capital via equity: year-to-date, $37.2 million through its at-the-market program and $21.5 million from a separate common stock issuance; Q3 also included 12.0 million pre-funded warrant exercises. As of November 4, 2025, 336,494,489 common shares were outstanding. Management states there is substantial doubt about the ability to continue as a going concern absent additional financing or partnerships.